Literature DB >> 21666346

Possible involvement of glutamatergic signaling machineries in pathophysiology of rheumatoid arthritis.

Eiichi Hinoi1, Yukio Yoneda.   

Abstract

The prevailing view is that L-glutamate (Glu) functions as an excitatory amino acid neurotransmitter through a number of molecular machineries required for the neurocrine signaling at synapses in the brain. These include Glu receptors for signal input, Glu transporters for signal termination, and vesicular Glu transporters for signal output through exocytotic release. Although relatively little attention has been paid to the functional expression of these molecules required for glutamatergic signaling in peripheral tissues, recent molecular biological analyses including ours give rise to a novel function for Glu as an extracellular signal mediator in the autocrine and/or paracrine system in several peripheral and non-neuronal tissues, including bone and cartilage. In particular, a drastic increase is demonstrated in the endogenous levels of both Glu and aspartate in the synovial fluid with intimate relevance to increased edema and sensitization to thermal hyperalgesia in experimental arthritis models. However, to date, there is only limited information about the physiological and pathological significance of glutamatergic signaling machineries expressed by articular synovial tissues. In this review, we have outlined the role of Glu in synovial fibroblasts in addition to the possible involvement of glutamatergic signaling machineries in the pathogenesis of joint diseases such as rheumatoid arthritis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21666346     DOI: 10.1254/jphs.11r03cr

Source DB:  PubMed          Journal:  J Pharmacol Sci        ISSN: 1347-8613            Impact factor:   3.337


  8 in total

Review 1.  The neurotransmitter glutamate and human T cells: glutamate receptors and glutamate-induced direct and potent effects on normal human T cells, cancerous human leukemia and lymphoma T cells, and autoimmune human T cells.

Authors:  Yonatan Ganor; Mia Levite
Journal:  J Neural Transm (Vienna)       Date:  2014-03-02       Impact factor: 3.575

2.  Pathway-based association analysis of two genome-wide screening data identifies rheumatoid arthritis-related pathways.

Authors:  M-M Zhang; Y-S Jiang; H-C Lv; H-B Mu; J Li; Z-W Shang; R-J Zhang
Journal:  Genes Immun       Date:  2014-08-07       Impact factor: 2.676

3.  Inhibitors of glutamate release from breast cancer cells; new targets for cancer-induced bone-pain.

Authors:  Jennifer Fazzari; Hanxin Lin; Cecilia Murphy; Robert Ungard; Gurmit Singh
Journal:  Sci Rep       Date:  2015-02-11       Impact factor: 4.379

4.  Glutamate signaling through the NMDA receptor reduces the expression of scleraxis in plantaris tendon derived cells.

Authors:  Christoph Spang; Ludvig J Backman; Sandrine Le Roux; Jialin Chen; Patrik Danielson
Journal:  BMC Musculoskelet Disord       Date:  2017-05-25       Impact factor: 2.362

Review 5.  Metabolic Control of Autoimmunity and Tissue Inflammation in Rheumatoid Arthritis.

Authors:  Jingtao Qiu; Bowen Wu; Stuart B Goodman; Gerald J Berry; Jorg J Goronzy; Cornelia M Weyand
Journal:  Front Immunol       Date:  2021-04-02       Impact factor: 8.786

6.  AMPA/kainate glutamate receptors contribute to inflammation, degeneration and pain related behaviour in inflammatory stages of arthritis.

Authors:  Cleo S Bonnet; Anwen S Williams; Sophie J Gilbert; Ann K Harvey; Bronwen A Evans; Deborah J Mason
Journal:  Ann Rheum Dis       Date:  2013-10-15       Impact factor: 19.103

Review 7.  Glutamate-Gated NMDA Receptors: Insights into the Function and Signaling in the Kidney.

Authors:  José M Valdivielso; Àuria Eritja; Maite Caus; Milica Bozic
Journal:  Biomolecules       Date:  2020-07-15

8.  Thousands of CpGs Show DNA Methylation Differences in ACPA-Positive Individuals.

Authors:  Yixiao Zeng; Kaiqiong Zhao; Kathleen Oros Klein; Xiaojian Shao; Marvin J Fritzler; Marie Hudson; Inés Colmegna; Tomi Pastinen; Sasha Bernatsky; Celia M T Greenwood
Journal:  Genes (Basel)       Date:  2021-08-29       Impact factor: 4.096

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.